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Summary
Background: The NO-modified form of the HIV inhibitor
saquinavir (Saq-NO) inhibited the growth of a variety of can-
cer cell lines in vitro and in vivo more potently than the orig-
inal compound in a nontoxic fashion. In addition, chemo-
and immunosensitizing properties were observed. The aim
of the present study was to evaluate its anticancer action
against non-small cell lung carcinoma cells in their doxoru-
bicin (DOXO) sensitive and resistant phenotype (NCI-H460
and NCI-H460/R). 
Methods: The viability of cells was analyzed by MTT and
crystal violet assays. DR5 expression was estimated by real
time RT-PCR and flow cytometry. Activity of P-glycoprotein
(P-gp) pumps was evaluated by the Rho123 accumulation
assay. 
Results: Saq-NO diminished the viability of lung cancer cells
through induction of cell cycle arrest in the G0/G1 phase in -
dependently of the overexpression of the P-gp pumps. In
addition, Saq-NO elevated or completely reconstituted the
doxorubicin efficacy in NCI-H460 and NCI-H460/R, respec -
ti vely. The chemosensitizing effect in DOXO resistant cells
was a consequence of P-gp inhibition which was found to be
Kratak sadr`aj
Uvod: Inhibitor HIV proteaze – sakvinavir nakon modifikaci-
je kovalentnim vezivanjem NO (Saq-NO) gubi toksi~na svoj -
stva dok potentnije od originalnog jedinjenja inhibira in vitro
i in vivo rast brojnih }elijskih linija kancera. Pored direktnog
antitumorskog delovanja, Saq-NO pove}ava osetljivost }elija
kancera na antitumorski imunski odgovor i konvencionalnu
hemioterapiju. Ova studija je imala za cilj ispitivanje antitu-
morskog potencijala Saq-NO na }elijskim linijama nesitno -
}elijskog karcinoma plu}a, senzitivnim (NCI-H460), odnos-
no rezistentnim (NCI-H460/R) na doksorubicin.
Metode: Vijabilitet }elija je evaluiran testovima MTT i »kristal
violet«. Ekspresija receptora DR5 je procenjivana me to dom
RT-PCR u realnom vremenu i proto~nom citofluori metrijom.
Aktivnost P-gp pumpi odre|ivana je akumulacio nim testom
Rho123. 
Rezultati: Saq-NO inhibira rast }elija kancera plu}a zausta -
vlja njem }elija u fazi G0/G1 }elijskog ciklusa a zapa`eni efe -
kat nije oslabljen pove}anjem ekspresije P-gp pumpi. Pored
toga, Saq-NO pove}ava osetljivost NCI-H460 }elija, dok u
slu~aju rezistentne forme, NCI-H460/R, potpuno rekonsti-
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Introduction
Lung cancer is a complex malignant disease
with a variety of histological types. Non-small cell lung
carcinoma (NSCLC) is one of the most frequent types
of lung cancer and it accounts for approximately 75%
of all lung carcinomas. Currently, chemotherapy
remains the mainstay of treatment; unfortunately, the
5-year survival of patients is still poor, fixed at 15%,
without significant improvement over the last two
decades (1).
Loss of sensitivity to death receptor-mediated
killing by immune system products, as well as the
rapid development of the chemoresistant phenotype,
are recognized as the leading causes of the low rate
of curability of NSCLC. Both phenomena are fre-
quently connected to the establishment of intracellu-
lar resistance to induction of apoptosis (2). Therefore,
new drugs with the ability to overcome this barrier
and remove the death pathway blockage are extreme-
ly desirable. Saquinavir-NO (Saq-NO) represents a
modality of the HIV protease inhibitor saquinavir.
Saqui navir (Saq) was created to inhibit the formation
of infective viral particles through blockage of the HIV
enzyme active site (3). However, it was found that this
drug effectively suppressed the development of HIV-
related malignancies or reduced their presence (4).
This property was subsequently investigated, and it
was shown that inhibition of the PI3K-Akt signaling
pathway and proteosome activity were connected
with its antitumor feature (4–12). Unfortunately, the
presence of side effects seriously limited Saq usage
and presented the opportunity for designing different
forms of this drug with an advanced pharmacological
profile (13). Attachment of the nitric oxide (NO) moi-
ety to saquinavir generated a new drug with signifi-
cantly improved antitumor characteristics (14). Saq-
NO was completely nontoxic in vitro and in vivo, while
its activity against a wide range of cell lines was qual-
itatively and quantitatively increased in comparison to
the parental drug (14). The novel agent was efficient
in numerous syngeneic and xenograft tumor models
without exhibiting any signs of biochemical or visible
toxicity (14–20). The unique mechanism of its tumo-
ricidal action includes nonaggressive inhibition of pro-
liferation due to suppression of S6 protein which is
important in the translation of 5’ terminal oligopyrim-
idine (TOP) containing mRNA and induction of differ-
entiation towards the normal nonmalignant pheno-
type (18). Apart from these important features,
Saq-NO was able to sensitize the tumor cells to
chemo- and immune response and therefore to pre-
vent the growth of tumors with an intrinsic resistance
to apoptosis (15, 18). Saq-NO was found to be effi-
cient in prostate cancer cells which overexpressed
MDR (20), but there are no published data concern-
ing the efficacy of Saq-NO against one of the most
aggressive forms of cancer, NSCLC, which is either
sensitive or resistant to chemotherapy. Results pre-
sented in this study clearly indicate that Saq-NO
nonselectively affected both NSLC phenotypes either
susceptible or not to the conventionally used chemo -
therapeutic drug doxorubicin. Besides its direct
antiproliferative potential, Saq-NO was effective
against both doxorubicin sensitive and resistant
NSCLC cell lines. Finally, Saq-NO amplified the
expression of TRAIL specific death receptor without
restoration of its functionality.
Material and Methods
Reagents and cells
Fetal calf serum (FCS), RPMI-1640, phosphate-
buffered saline (PBS), dimethyl sulfoxide (DMSO),
and propidium iodide (PI) were obtained from Sigma
(St. Louis, MO). The NCI-H460 human non-small
lung carcinoma cell line was purchased from the
American Type Culture Collection (ATCC) (Manassas,
VI). Cells were routinely maintained in HEPES-
buffered RPMI-1640 medium supplemented with
10% FCS, 2 mmol/L L-glutamine, 0.01% sodium
pyruvate, and antibiotics (culture medium) at 37 °C in
a humidified atmosphere with 5% CO2. After
trypsinization, cells were seeded at 4 × 103/well in
96-well plates for viability determination and 1.5 ×
more potent than that observed with dex-verapamil, a con-
ventional inhibitor of P-gp. Sensitization to DOXO upon Saq-
NO was accompanied by elevated DR5 expression, but the
resistance to TRAIL was not abrogated. 
Conclusions: The NO-modified HIV inhibitor saquinavir dis-
played equal antiproliferative and chemosensitizing proper-
ties in DOXO sensitive and resistant non-small cell lung car-
cinoma cells, suggesting the importance of the evaluation of
this drug as an antineoplastic agent.
Keywords: chemosensitization, non-small cell lung carci-
noma cells, saquinavir, saquinavir-NO, tumor
tui{e njihovu osetljivost na doksorubicin. Efekat hemosenziti-
zacije je posledica inhibicije P-gp pumpi, {to Saq-NO ~ini
potentnijim od deksverapamila, uobi~ajenog inhibitora P-gp.
Opisani fenomen je pra}en pove}anjem ekspresije receptora
DR5 na genskom i membranskom nivou, ali time rezisten cija
na molekul TRAIL nije ukinuta. 
Zaklju~ak: Saq-NO pokazuje zna~ajan antiproliferativan i
hemosenzitizuju}i potencijal na }elijama nesitno}elijskog
kancera plu}a nezavisno od njihove osetljivosti odnosno
rezistencije na doksorubicin, ukazuju}i na potrebu daljeg
ispitivanja ovog jedinjenja u svojstvu potencijalnog antineo-
plasti~nog agensa.
Klju~ne re~i: tumor, sakvinavir, sakvinavir-NO, nesitno -
}elijski karcinom plu}a, hemosenzitizacija
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105/well in 6-well plates for flow cytometric analysis.
Resistant NCI-H460/R cells were selected originally
from NCI-H460 cells by exposure to gradually
increasing concentrations of doxorubicin (21). 
Determination of cell viability by MTT 
and crystal violet assay
For the determination of cell viability, the crystal
violet (CV) and mitochondrial dehydrogenase tests
(MTT) were performed. Cells (4 × 103/well) were
cultivated in the presence of a wide range of drug
doses for 48 h and viability was determined as previ-
ously described (22). The results are presented as
percentage of the control (untreated cells), that was
arbitrarily set to 100%. 
Cell cycle analysis
Cells were treated with 18.8 mmol/L of Saq and
Saq-NO, trypsinized and fixed in 70% ethanol at 4 °C
overnight. Cells were stained with a solution contain-
ing PI (20 mg/mL) and RNase (0.1 mg/mL) for 30
min at 37 °C in the dark. After each step, cells were
washed with PBS, and red fluorescence was analyzed
on a FACS Calibur flow cytometer (BD, Heidelberg,
Germany). The distribution of cells in different cell
cycle phases was determined with Cell Quest Pro soft-
ware (BD) (23). 
Isobologram analysis
Isobologram analysis was used to determine the
type of interaction between Saq-NO and recombinant
human TRAIL. Isobolograms were created after treat-
ment with a wide range of Saq-NO concentrations
(4.7–18.8 mmol/L) with different concentrations of
TRAIL (6.2–50 ng/mL). Combinations reaching
30–70% of cytotoxicity were expressed as concentra-
tion of single agent alone leading to the observed
amount of toxicity. Analysis was done using dose-
response curves after exposure to Saq-NO alone,
TRAIL alone, or their combination for 24 h (15, 24).
RNA isolation and relative quantification of DR5
mRNA by real time RT-PCR
Total RNA was isolated from NCI-H460 and
NCI-H460/R cells using TRIZOL reagent (Invitro gen,
Carlsbad, CA) according to the manufacturer’s in -
structions. Two mg of RNA were converted to cDNA
by reverse transcription (RT) reactions in a 100 mL
volume with random hexamer primers using High-
Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, USA) following the manufacturer’s
instructions. The reactions were performed under
RNase-free conditions at 25 °C for 10 min and 37 °C
for 2 h. Each RT reaction was accompanied by a no-
RT control in which the reverse transcriptase was
replaced by DEPC treated water.
The expression of DR5 mRNA was evaluated by
SYBR Green (Applied Biosystems) real time RT-PCR.
PCR was performed using ABI Prism 7000 Sequence
Detection System (Applied Biosystems) in a total vol-
ume of 25 mL containing 1× SYBRGreen PCR mas-
ter mix with AmpErase UNG (Applied Biosystems),
0.5 mmol/L primers and cDNA template (20 ng of
RNA converted to cDNA) at cycle conditions: 2 min
at 50 °C for dUTP activation, 10 min at 95 °C for ini-
tial denaturation and Taq polymerase activation, fol-
lowed by 40 cycles at 95 °C for 15 s and 60 °C for 60
s. Primer pairs (Sigma) were: for DR5 5’-TGC AGC
CGT AGT CTT GAT TG-3’ and 5’-GCA CCA AGT
CTGCAAAGTCA-3’ and for GAPDH 5’-CATCCAT-
GACAACTTTGG TAT CG-30 and 5’-CCA TCA CGC
CAC AGT TTC C-3’. The experimental threshold was
calculated from the mean baseline fluorescence sig-
nal from cycle 3 to 15, plus 10 standard deviations.
The point at which the amplification plot crosses this
threshold is defined as Ct. No template control was
used in each run. Each sample was run in triplicate
and a mean value of each Ct triplicate was used for
further calculation. A reference, endogenous control,
was included in every analysis to correct the differ-
ences in inter-assay amplification efficiency, and the
expression of each gene was normalized to GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) expres-
sion. Quantification was performed by the 2-DDCt
method (25). The results obtained were analyzed by
RQ Study Add ON software for 7000 v 1.1 SDS
instrument (ABI Prism Sequence Detection System)
with a confidence level of 95% (p<0.05).
DR5 membrane expression
The expression of DR5 was assessed by flow
cytometry as previously described (24). After the 24 h
of treatment with 18.8 mmol/L, Saq-NO cells were
detached with PBS-EDTA (1 mmol/L), incubated in
PBS–10% FCS for 1 h for membrane reconstitution,
and then stained with anti-DR5 antibody (mouse anti-
human DR5, Biosource International, Camarillo, CA)
45 min at RT. After washing in PBS–0.5% BSA, cells
were incubated for 30 min at RT with secondary
TRIC-conjugated goat anti-mouse IgG (ZymedTM,
Invitrogen) washed twice with PBS–0.5% BSA and
finally resuspended in PBS. Analysis was performed
on a FACS Calibur flow cytometer using CellQuest
software.
Rho123 accumulation assay 
Rho123 accumulation was analyzed by flow
cytometry utilizing the ability of Rho123 to emit fluo-
rescence. The intensity of the fluorescence was pro-
portional to Rho123 accumulation. Studies were per-
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formed with dex-VER and Saq-NO. NCI-H460/R cells
were grown to 80% confluence in 75 cm2 flasks,
trypsinized and resuspended in 10 mL centrifuge
tubes in a Rho123-containing medium. Then, the
cells were treated with Saq-NO and VER (18.8
mmol/L) and incubated at 37 °C in 5% CO2 for 30
min. At the end of the incubation period, the cells
were pelleted by centrifugation, washed with PBS and
placed in cold PBS. The samples were kept on ice in
the dark until analysis on a FACS calibur flow cytome-
ter (Becton Dickinson, Oxford, United Kingdom). The
fluorescence of Rho123 was assessed on fluores-
cence channel 2 (FL2-H) at 530 nm. A minimum of
10,000 events were assayed for each sample. The
differences in curve shape were quantified using a
Kolmogorov–Smirnov nonparametric statistic. P val-
ues were calculated (available on request) in
CellQuest Pro and run on a Macintosh computer.
Statistical analysis
The results are presented as mean ± SD of trip-
licate observations from the representative of three
experiments, except if indicated otherwise. The signif-
icance of the difference between treatments and con-
trol was analyzed by ANOVA followed by Stu -
dent–Newman–Keuls test. P<0.05 was considered
significant. 
Results
Saq-NO decreased the viability of both 
doxorubicin sensitive and resistant NSCLC cells
To investigate the effects of Saq-NO and Saq on
the viability of sensitive NSCLC cells (NCI-H460) and
compare it with their potential to inhibit the growth of
doxorubicin resistant NSCLC cells (NCI-H460/R),
cells were exposed to a wide range of doses for 48 h
when the number of viable cells was measured by
both MTT and CV assays. As can be seen in Figure 1,
Saq-NO decreased the mitochondrial respiration (left
panel) and the viability (right panel) of NCI-H460
cells more potently than its parental drug, Saq.
Importantly, the same pattern of action of the HIV
protease inhibitor and its NO-modified form was
observed in the doxorubicin resistant form of this cell
line. The results obtained from the viability assays
clearly indicated that NO-modified Saquinavir pos-
sesses stronger potential to suppress the growth of
doxorubicin sensitive and resistant non-small lung
carcinoma cells than the original drug (Figure 1A). It
was previously observed that Saq-NO acted basically
through decreasing their dividing potentials. To deter-
mine the reason for the abrogated viability observed
in NCI-H460 or NCI-H460/R cells after exposure to
Saq-NO, cell cycle distribution was estimated. For that
purpose, NCI-H460 and NCI-H460/R cells were
incubated for 48 h with doses at the IC50 level. Flow
cytometric analysis revealed a remarkable G0/G1
arrest in cultures exposed to the drug independently
from their sensitivity to doxorubicin. In parallel with
this, an insignificant amount of hypodiploid cells was
detected upon the treatment indicating that inhibition
of proliferation rather than apoptosis was responsible
for the diminished number of cells observed after the
treatment with Saq-NO. Ann/PI double staining con-
firmed the absence of both early and late apoptotic
cells in NCI-H460 and NCI-H460/R cells (data not
shown) confirming the nonaggressive  suppression of
tumor cell growth. In summary, overexpression of P-
gp in NSCLC cells did not alter the capacity of Saq-
NO to downregulate the rate of cell division and
decrease their malignant potential.
Saq-NO increased the sensitivity of NSCLC cells
to doxorubicin
Since we observed that Saq-NO was equally effi-
cient against doxorubicin sensitive and resistant cells,
it was of interest to evaluate its capacity to provoke or
to revert the sensitivity to the chemotherapeutic drug.
NCI-H460 and NCI-H460/R cells were treated with
Saq-NO for 4 h prior to doxorubicin application. Cell
viability was measured by the CV test after the 48 h.
As shown in Figure 2A, Saq-NO amplified the toxicity
of doxorubicin in both sensitive and resistant cells
under these experimental conditions. These effects
were observed when the cells were exposed to both
treatments simultaneously. The viability of cells simul-
taneously treated with Saq-NO and doxorubicin was
significantly lower in comparison to their viability
when treated with doxorubicin alone and the effect
was more obvious on NCI-H460/R cells, as expected
(Figure 2B). Importantly, the chemosensitizing capa -
city of Saq-NO was more potent than the one ob -
 served with the P-gp inhibitor dex-verapamil, or origi-
nal drugs in the same doses (4.5 left or 9 mmol/L,
right) (Figure 2C). Taken together, Saq-NO is able to
sensitize the resistant cells to one of the most fre-
quently used chemo therapeutic drugs, doxorubicin,
and to decrease the efficient dose in sensitive clones.
Saq-NO blocked the P-gp pumps
The ability of Saq-NO to sensitize the resistant
NCI-H460/R cells to doxorubicin indicated the possi-
bility that the target for its action are P-gp pumps
which are overexpressed in these cells. To evaluate
this hypothesis, the cells were exposed to 18.8
mmol/L of either Saq-NO or dex-verapamil for 30 min
and then the capacity of the cells to export the
Rho123 stain was measured by flow cytometric analy-
sis (Fi gure 3). Cells exposed to Saq-NO exhibited
increased Rho123 fluorescence, confirming that Saq-
NO blocked the P-gp pumps more potently than the
commercial P-gp inhibitor dex-verapamil.
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Figure 1 Saq-NO decreased viability of both DOXO-sensitive and DOXO-resistant human NSCLC cell lines. A, NCI-H460 and
NCI-H460/R cells (4 × 103 cells/well) were treated with a range of concentrations of Saq or Saq-NO for 48 h after which cell
viability was estimated by MTT  (left panel) and CV (right panel) tests. The data are presented as the mean ± S.D. from a repre-
sentative of three independent experiments. *, p <0.05, refers to untreated cultures. B, Cells were treated with IC50 dose (18.8
mM) of Saq-NO or left untreated (control) and cell cycle analysis was performed by flow cytometry after 48 h. 
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Figure 2 Saq-NO is more potent than dex-verapamil in sensitizing human NSCLC cells to DOXO. NCI-H460 and NCI-H460/R
cells (4 × 103 cells/well) were pretreated with various doses of Saq-NO for 6 h (A) or simultaneously treated with a range of DOXO
concentrations (B). After 48 h of DOXO treatment, cell viability was estimated by CV. C, NCI-H460/R cells (4 × 103 cells/well)
were simultaneously treated with 4.7 mmol/L (left panel) or 9.4 mmol/L (right panel) of dex-ver, Saq or Saq-NO and with a range
of concentrations of DOXO and after 48 h cell viability was evaluated by CV. The data are presented as the mean ± S.D. from a
representative of three independent experiments. *, p <0.05, refers to untreated cultures.
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Figure 4 SSaq-NO upregulated DR5 expression at mRNA and membrane level. NCI-H460 (A) and NCI-H460/R (B) cells were
treated with Ver or Saq-NO (18.8 mmol/L for 24 h and qRT PCR analyses for DR5 mRNA was performed (upper panels) or cells
were treated with Saq, Saq-NO, dex-Ver or TQ (18.8 mmol/L) for 24 h after which DR5 membrane expression was analyzed by
flow cytometry (lower panels).
Figure 3 Saq-NO inhibited P-gp activity. NCI-H460/R cells were treated with Saq, Saq-NO or dex-ver (18.8 mmol/L) or left
untreated (control) for 30 min and Rho123 accumulation was analyzed by flow cytometry.
Saq-NO increased the expression of death
receptor 5 (DR5) 
One of the main characteristics of NSCLC, which
is often associated with the resistance to apoptosis
induced by chemotherapy, is its loss of membrane
death receptors able to bind the TRAIL molecule, one
of the most potent products of the immune system in
elimination of cancer cells (26, 27). To evaluate the
possible influence of Saq-NO on DR5 gene expression,
cells were exposed to 18.8 mmol/L of either Saq-NO or
dex-verapamil and the expression of DR5 was exam-
ined by real-time RT-PCR. Both drugs elevated DR5
mRNA expression in sensitive NCI-H460 cells, while in
NCI-H460/R cells significant gene expression of this
re ceptor was observed under the Saq-NO but not
dex-verapamil treatment (Figure 4 upper panel). DR5
expression correlated with its presence on the mem-
brane of cells (Figure 4 lower panel). While the compet-
itive inhibitor, dex-verapamil, and the noncompetitive
inhibitor, tariquidar (TQ), did not alter the presence of
DR5 on the membrane of either NCI-H460 or NCI-
H460/R cells, the expression of this receptor was ele-
vated after the exposure to Saq-NO.
Saq-NO antagonized the TRAIL activity
The potential of Saq-NO to elevate the expres-
sion of DR5 indicated its possibility to reverse the sen-
sitivity of these cells to selective antitumor response
driven by ligation of TRAIL to this receptor. To clarify
this possibility, NCI-H460 and NCI-H460/R cells
resistant to TRAIL were treated in parallel with this
molecule and Saq-NO (Figure 5). Cell viability was
estimated by MTT tests and isobologram curves were
created. Unfortunately, interaction between Saq-NO
and TRAIL was antagonistic suggesting that, apart
from Saq-NO potential to amplify the DR5 expres-
sion, it was not able to exclude blockage at the intra-
cellular level which may be responsible for the ineffec-
tive response to TRAIL.
Discussion
Numerous studies performed during the last
decade indicate that antiinflammatory or antimicro-
bial drugs could target cancer cells (28). One of the
promising candidates are the HIV protease inhibitors
which, due to the inhibition of PI3K/Akt signaling
pathway and proteasome activity, suppress the growth
of not just HIV-related malignancies but also various
types of tumors (4–12). Poor pharmacological profile
of these drugs as well as high toxicity seriously com-
promised their utilization and indicated the need for
their modification (13). In order to improve its quali-
ty, we attached a NO moiety to Saq (14). Recently, we
found that NO-modified Saq efficiently inhibited the
progression of tumor cells derived from rodent or
human origin in vitro as well as in syngeneic and
xenograft models (14–19). An absence of Saq-NO
toxicity was observed on primary cells in vitro and was
further confirmed by studies of acute and subacute
toxicity (14).  The results revealed the impressive fact
that the NO-modified compound was completely
innoxious when it was applied in a dose correspon-
ding to a 100% lethal dose of parental drug. A major
aspect of Saq-NO action was its capacity to stop the
tumor growth in a nonaggressive manner. Rodent
melano ma, glioma cells and colon cancer cells under-
went the process of differentiation/transdifferentia-
tion after time-limited exposure to Saq-NO (14, 19).
Loss of their malignant potential and metastatic
capacities were accompanied by chemosensitization
as well as reconstitution of their sensitivity to the
TRAIL-mediated immune response (15, 18). More -
over, its efficacy was impressive even in multidrug
(MDR) resistant forms of prostate cancers (20).
NSCLC is one of the most aggressive forms of tumor
which during its progression loses the sensitivity to
death receptor-mediated antitumor activities and
response to chemotherapy. NSCLC rapidly progresses
to the apoptotic resistant form (2). Here, we have
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Figure 5 Lack of Saq-NO sensitization of human NSCLC
cells to TRAIL-mediated apoptosis. NCI-H460 (A) and NCI-
H460/R (B) cells were treated with IC30 dose of Saq-NO
(9.4 mmol/L) for 6 h after which various concentrations of
human recombinant TRAIL were added and further incubat-
ed for 18 h. Viability of cells was accessed by CV and isobolo-
gram curves from representative of three experiments are
presented. Fractional inhibitory concentration (F.I.C.) > 1 is
considered antagonistic.
compared the capacity of Saq-NO to downregulate
the growth of two phenotypes of NSCLC, sensitive
and resistant to doxorubicin. As previously observed
in a panel of cell lines, Saq-NO exerted tumoricidal
effects in lower concentrations than Saq which was
independent from the expression of P-gp pumps
(14–20). Similarly to our previous observations, Saq-
NO induced cell cycle arrest in the G0/G1 phase and
therefore decreased the proliferation of NSCLC. The
ability to stop the growth of both types of NSCLC,
sensitive and resistant, is very important to determine
the role of P-gp in cancer cells that limit the applica-
tion of chemotherapy. ATP-dependent pumps are
responsible for the transfer of substances across bio-
logical membranes and, therefore, drugs across tis-
sue barriers in cancer cell chemoresistant phenotypes
(29–32). Saq-NO application 4 h before or simulta-
neously with DOXO decreased the efficient dose of
this chemotherapeutic drug in sensitive cells and,
more importantly, sensitized the resistant cells to this
chemotherapeutic drug. Recently, it was observed
that Saq can be a substrate of P-glycoprotein and also
an inhibitor of the breast cancer resistance protein
(BCRP1, gene product of ABCG2) (33–36). On the
other hand, Rotwailer et al. demonstrated that Saq-
NO sensitized P-gp–, MRP1-, or BCRP1-expressing
prostate cancer cells to chemotherapy. Similarly, in
NSCLC cells, Saq-NO inhibited the P-gp more effec-
tively than the competitive inhibitor dex-verapamil
(20). This is important due to the known toxicity of
competitive ATP-Binding Cassette (ABC) transporter
inhibitors and, therefore, the development of new less
toxic drugs with the capacity to inhibit ABC trans-
porters could be beneficial (29, 32, 37, 38). Namely,
simultaneous administration of anticancer drugs and
compounds that can impede the efflux of chemother-
apeutic agents by ABC transporters can concomitant-
ly modulate various cytochrome P450 (CYP450)
enzymes, consequently influencing their anticancer
drug metabolism. This can further result in unfavor-
able drug–drug interactions and altered pharmacoki-
netic properties of the applied anticancer drugs with
additional adverse cytotoxic side effects (39). Thus,
the first generation of P-gp inhibitor drugs confirmed
the effect of a P-gp modulation to overcome MDR,
but most of these drugs had limited clinical imple-
mentation because the administered doses were
either noneffective or toxic for the patient. The sec-
ond generation of P-gp inhibitors had reduced pri-
mary toxicity, however, they showed important phar-
macological interactions which caused disturbed
metabolism and accumulation of chemotherapeutic
drugs, what finally lead to exaggerated toxicity as
well. Finally, the third generation of inhibitors was
designed for low pharmacokinetic interactions and
high transporter affinity, but their efficacy has not yet
been confirmed by clinical evidence summarized in
Szakács et al. (29).
In addition to its potential to restore sensitivity to
chemotherapy through drug pump inhibition, equal
efficacy of Saq-NO against the sensitive and resistant
type of NSCLC cells indicated that transporter pro-
teins are not the barrier for its intrinsic capacity to
effectively stop the division of non-small lung cancer
cells.  Moreover, strong antitumor potential observed
in vitro was not accompanied by the induction of cell
death. This is a very important feature of the Saq-NO
mode of action, if it is well defined that induction of
apoptosis is an undesirable way to treat the cancer in
highly aggressive forms, such as this type of cancer.
Having in mind that NSCLC rapidly adopts an apop-
totic resistant phenotype in response to chemothera-
py, it seems that efficacy of Saq-NO could be ascribed
to its potential to inhibit the proliferation of these cells
rather than kill them (2). 
Development of an apoptotic resistant pheno-
type is often correlated with the loss of sensitivity to
death signals triggered by immune cell products such
as TRAIL (26, 27). This molecule is one of the most
selective mediators of tumor cell death able to induce
the apoptosis of transformed but not normal cell after
ligation to its specific receptor. Cancer cells evade this
through the lack of expression of its receptors or devel-
opment of intracellular blockage in delivering the
death signal triggered upon ligation. Saq-NO was able
to upregulate the expression of DR5 in both DOXO
sensitive and resistant cancer cells. In spite of this,
TRAIL was not able to induce the apoptotic process. It
is obvious that intracellular blockade responsible for
apoptotic resistance was not eliminated by Saq-NO
application. It was previously observed that Saq-NO
efficiently res tores the TRAIL-mediated antitumor res -
ponse not just through upregulated expression of DR5
but also  through a decrease in the expression of nat-
ural caspase-3 inhibitor XIAP in prostate cancer (18).
The explanation of the unsuccessful immunosensitiza-
tion by Saq-NO under these circumstances could be
related to the described feature of NSCLC cells to be
unable to mediate the posttranslational modifications
of DRs and/or to bring to the membrane their non-
functional forms (26, 27). These data are in dishar-
mony with the previously found enhancement of
TRAIL-induced apoptosis in P-gp-overexpressing
leukemia and breast cancer cells, indicating that the
intrinsic characteristics of cancer cells are crucial for
the outcome of the treatment (40, 41). The capability
of Saq-NO to function in a slow cytostatic and differ-
entiating manner, and its potential to nonselectively
target various types of tumors, even the most aggres-
sive MDR forms, draw attention to the importance of
further analysis of this class of drugs as antineoplastic
agents.
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